Vivos Inc.  announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals.

The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, development of clinician training modules, and educational seminars.

“Our companies complement one another exceptionally well,” said Dr. Michael K. Korenko, Chief Executive Officer of Vivos Inc. “Exubrion’s focus on treating osteoarthritis pain in companion animals and Vivos’s work in cancer therapy represent distinct markets, enabling collaboration without competitive conflict. By aligning our scientific and operational strengths, we can accelerate innovation and efficiency across both organizations.”

Dr. Korenko added, “It is our shared responsibility to continuously pursue improvements that drive success. With only a limited number of companies developing therapeutic applications of radioactive isotopes, cooperative innovation is key to advancing this field.”

“I’m excited to collaborate with the Vivos team to help further this important work,” said Jennifer Kirk, Chief Executive Officer of Exubrion Therapeutics. “Together, we can accelerate progress in advancing the use of radioisotopes as a powerful and versatile technology platform with wide-ranging potential.”